KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Cost of Revenue (2020 - 2023)

AbCellera Biologics' Cost of Revenue history spans 4 years, with the latest figure at $3.1 million for Q4 2023.

  • For the quarter ending Q4 2023, Cost of Revenue rose 106.67% year-over-year to $3.1 million, compared with a TTM value of $10.7 million through Dec 2023, down 51.36%, and an annual FY2024 reading of $12.8 million, down 9.88% over the prior year.
  • Cost of Revenue for Q4 2023 was $3.1 million at AbCellera Biologics, down from $3.8 million in the prior quarter.
  • The five-year high for Cost of Revenue was $25.5 million in Q4 2020, with the low at $437000.0 in Q1 2020.
  • Average Cost of Revenue over 4 years is $4.6 million, with a median of $2.6 million recorded in 2021.
  • Year-over-year, Cost of Revenue tumbled 92.83% in 2021 and then soared 1135.41% in 2022.
  • Tracing ABCL's Cost of Revenue over 4 years: stood at $25.5 million in 2020, then tumbled by 92.83% to $1.8 million in 2021, then dropped by 17.9% to $1.5 million in 2022, then soared by 106.67% to $3.1 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Cost of Revenue are $3.1 million (Q4 2023), $3.8 million (Q2 2023), and $3.8 million (Q1 2023).